Company profile
UK company 04225086, incorporated on 30 May 2001.
Physiomics | Physiomics - Oncology Drug Development | Pharmaceutical Consulting
Physiomics is a leading oncology drug development consultancy using proprietary state of the artVirtual Tumour technology and other tools to predict and better understand the effects of cancer treatments. We work with partners developing cancer drugs to help them save time and money during pre-clinical and clinical development.
Company number 04225086
Updated 07 Jul 2026 09:49
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
1 Nov 2023 to 31 Mar 2026
Patients with advanced cancers are often treated with chemotherapy which can reduce the effectiveness of the body's own immune system and leave patients exposed to infection. The manufacturers of chemotherapy drugs generally suggest using the same amount of drug for everybody who needs it, however, we know that because everyone is different, people end up...
1 Apr 2018 to 31 Mar 2019
"Precision medicine heralds a new era of cancer care where each patient receives the right drug at the right dose and time specific to their needs. However, the practice of precision dosing is hampered by a lack of smart dosing algorithms. The choice of chemotherapy dose in the clinical practice is predominantly based on Body Surface Area (BSA) which is d...
1 Feb 2017 to 31 Jan 2018
Stratified medicine is a medical model in which patient group data are taken into account to tailor treatment. Various data, including pharmacogenomic data, are used to customise the treatment plan for these patient groups. In oncology, this treatment plan can involve chemotherapy, radiation and surgery. Deciding which treatments to use, and when to apply...
1 Jul 2013 to 31 Mar 2014
Personalised medicine can be broken down into three key questions: which drugs do we give to a particular patient, how much and when? While many companies are seeking to address the first question, dosing and scheduling issues are poorly understood. Attrition rates in oncology remain high, part of the problem being that dosing and scheduling regimens are ...
